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Ketamine (IM) Assisted Psychotherapy (KAP):
A Model for Informed Consent
Informed consent is important for every medical intervention, and the unique nature of ketamine 
assisted psychotherapy (KAP) calls for a particularly thoughtful and detailed informed consent 
document. The following is an informed consent form developed for the author’s use in his own private 
practice. No representations are made concerning its adequacy or appropriateness for use by other 
practitioners, or in any other contexts; author, editors, and publisher disclaim liability for any use of or 
reliance on this document. However, as a document created by a psychiatrist with experience in KAP, 
this form may serve to illustrate the range of issues that an informed consent document might address.
International Journal of Transpersonal Studies, 33(2), 2014, pp. 185-192 
Philip E. Wolfson
Center for Transformational Psychotherapy
San Francisco and San Anselmo, CA, USA
Ketamine (IM) Assisted Psychotherapy 
Informed Consent Form
What is Ketamine?
Ketamine is now a validated “off-label” treatment for various chronic “treatment-resistant” mental illnesses. Ketamine is a Schedule III medication that has long been used safely 
as an anesthetic agent and now, at times, effectively as treatment for depression, alcoholism, 
substance dependencies, PTSD and other psychiatric diagnoses.
How Does It Work?  
The current, most probable, understanding of ketamine’s mode of action is as an NMDA antagonist working through the glutamate neurotransmitter system. It is classified as a 
dissociative anesthetic. At the dosage level administered to you, you will most likely experience 
analgesic, anxiolytic, antidepressant, and psychedelic effects. Ketamine also may bring about 
“transpersonal,” “mystical,” or “out-of-body” experiences that may also serve to facilitate a shift 
in your perspective and emotional state.  
Monitoring
It is essential that you be followed very closely during and after your treatment. This will include blood pressure and pulse measurements, some psychological measurements before 
and after your session, close supervision and support during your treatment session with your 
physician/psychiatrist/psychotherapist, and follow-up telephone and in-person contact with 
your treatment team.
You will be entering a psychotherapy program that will prepare you for your ketamine 
session(s) and assist you in integrating your experience(s) afterwards. This program emphasizes 
the possibilities for change and the seriousness of your and our effort to assist you.
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How Long Will It Take Before I Might See Beneficial Effects? 
You may experience important changes in personality, mood, and cognition during treatment, in the immediate aftermath, and in the days and weeks that follow. Some experiences may 
be temporarily disturbing to you. The ketamine experience itself is designed to enable your 
own healing wisdom to be accessed and beneficial to you. The psychotherapeutic support you 
will receive will aid you in making your experience(s) valuable and understandable to you. 
Some experiences may be temporarily disturbing, but the integration process may greatly help 
you move to clarity and understanding. 
Why Ketamine (IM) Assisted Psychotherapy?
The purpose of KAP is to create a non-ordinary (“altered”) state of consciousness in order to facilitate profound transpersonal (“transcendental,” “mystical,” “spiritual,” 
“religious”) peak experiences that may be beneficial in resolving your existential problems, 
accelerating your psycho-spiritual growth and lead you to a deep personal transformation and 
optimization of your lifestyle. Such change is best facilitated within a structured supportive 
psychotherapeutic milieu in connection with therapists who have a view of your issues, hopes, 
desires, and struggles. As a byproduct of your experience you may well feel improvement in 
your emotional state and reduction in symptoms that bother you such as depression, anxiety, 
and post-traumatic manifestations. You may notice that you are a bit different after a ketamine 
experience and that difference may well be liberating and allow for new mindfulness and new 
behavior. It is frequently the case that a ketamine experience may promote happiness, empathy, 
loving-kindness to self and others, and a sense of greater self-acceptance and peacefulness.
Your experience will be unique to you. If you and we decide to have additional sessions 
using ketamine, each of your sessions will be different. All such journeys are adventures that 
cannot be programmed. They evolve from your own being in relation to this substance. While 
it is best to form an intention for your journey, you may or may not be able to hold onto that.
Indeed, no holding on is best and the journey will flow whether or not you hold on and resist, 
or follow the path that unfolds and relax into it. Holding on is the main source of anxiety 
in this and other related journeys. A ketamine session can be light, dark, or both. There will 
be concepts, visions, encounters, and you may well deal with your own death, mortality, and 
immortality. Not everyone enjoys the journey, but everyone comes through it—and generally 
with a measure of positive change and a sense of having had a profound experience that may 
be life changing indeed.
Eligibility for KAP
This consent form contains information about the use of sub-anesthetic dosages of ketamine for psychiatric purposes including depression. Ketamine was approved by the FDA for 
use as an anesthetic agent several decades ago. Ketamine has an extensive record of safety and 
has been used at much higher doses for surgical anesthesia, without respiratory depression. The 
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administration of ketamine in lower, sub-anesthetic doses to treat pain, depression, or other 
psychiatric diagnoses is a newer, off-label use of ketamine. Psychiatric use of ketamine has 
become relatively widespread in recent years, has been studied and promoted by researchers at 
the National Institute of Mental Health, and has had publicity as the newest anti-depressant 
with its own novel pharmacological mechanism of action. Ketamine has been administered 
by intravenous, intramuscular (IM), and intranasal routes. Often, it has been used after other 
treatment approaches have been unsuccessful.
 Once you indicate that you have understood the benefits and risks of this treatment, 
you will be asked to sign this form in order to participate in this treatment. You will be given 
a signed copy of this form to keep for your own records. This process is known as giving 
informed consent.
By signing this document, you indicate that you understand the information provided 
and that you give your consent to the medical procedure to be performed during your 
participation in ketamine treatment. Please read this consent form carefully, and feel free to 
ask questions about any of the information in it.
Participation in Ketamine Assisted Psychotherapy
Before participating in ketamine treatment, you will be carefully interviewed to determine whether you are eligible for ketamine therapy, including a medical history, a physical exam 
if deemed necessary, review of your medical/psychiatric records, a psychiatric history and 
administration of brief psychological tests to assess your state of mind. 
• Pregnant women and nursing mothers are not eligible because of 
potential effects on the fetus, or nursing child. The effects of ketamine 
on pregnancy and the fetus are undetermined, and therefore, it is 
advisable to protect against pregnancy while exposing yourself to 
ketamine or in the immediate aftermath of its use.
• Untreated hypertension is a contra-indication to ketamine use as 
the substance causes a rise in blood pressure. Similarly, a history of 
heart disease may make you ineligible to participate.
• Information on ketamine’s interaction with other medicines is only 
partially available and it will be assessed as to your eligibility for 
KAP.
• Ketamine should not be taken if you have hyperthyroidism. There 
have also been reports of some decrease in immune function in 
patients receiving surgical doses of ketamine.
Ketamine has an extensive record of safety and has been used at much higher doses for 
surgical anesthesia, without respiratory depression, making it an ideal anesthetic agent.
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Overview of Ketamine (IM) Assisted Therapy—KAP
During the Ketamine administration session, you will be asked to make two (2) agreements with the therapist(s) to ensure your safety and well-being:
• You agree to follow any direct instructions given to you by the 
therapist(s) until it is determined that the session is over, and
• You agree to remain at the location of the session until the therapist(s) 
decides you are ready to leave.  
 The length of ketamine sessions varies from person-to-person and from experience-
to-experience. You will be mostly internally focused for the first 45 minutes to one-hour-
and-a-half following IM administration of ketamine. You will continue to remain under 
ketamine’s influence at a lesser level for at least one hour. Under my care, ketamine will be 
given as an intramuscular injection into the shoulder or buttocks at doses of 50 mg or 100 mg 
(130mg maximally). The choice of dose will depend on prior exposure to ketamine and other 
psychedelics. Naïve subjects will receive a lower dose in the initial session. It is always better 
to start with a lower dose to reduce anxiety and become familiar with what a substance may 
produce in you. There is always an opportunity to make a choice for a larger dose at a future 
date—if appropriate. It is more difficult to correct a bad experience because of too high an 
initial dose and the anxiety it may engender. Individuals experienced with psychedelics may 
receive a higher initial dose. Ketamine IM creates an unusual experience of formlessness and 
a dissolving of boundaries and has novel effects on the mind. Therefore, it is much better to 
have an initial learning experience for familiarization with ketamine and its effects on you.
Preparation for a ketamine session requires assessment by your therapist of your 
readiness and a sense of connection between you and your therapist. We are engaging in 
a therapeutic endeavor to benefit you and those who are affected by you. Together, we are 
creating a therapeutic state that is based on rapport and trust (set) in a safe and conducive 
setting. That will require prior sessions to your use of the drug. After ketamine IM use, you 
will have follow-up sessions that focus on integration of your experience and may lead to 
further sessions, if you so wish, and if that is in accord with your therapist’s view of your 
treatment. 
You may ask the therapist(s) any questions you may have concerning the procedure or 
effects of ketamine at any time. Your consent to receive ketamine may be withdrawn by you, 
and you may discontinue your participation at any time up until the actual injection has been 
given.
Potential Risks of Ketamine (IM) Assisted Therapy 
You will be asked to lie still during the ketamine administration because your sense of balance and coordination will be adversely affected until the drug’s effect has worn off—
generally two and up to four hours after the injection. Other possibilities for adverse effects 
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include blurred and uncomfortable vision (you are advised to keep your eyes closed until the 
main effects have worn off), slurred speech, mental confusion, excitability, diminished ability 
to see things that are actually present, diminished ability to hear or to feel objects acccurately 
including one’s own body, anxiety, nausea and vomiting. Visual, tactile and auditory processing 
are affected by the drug. Familiar music may appear quite different to you, even unrecognizable. 
Synesthesia, a mingling of the senses, may occur. Ordinary sense of time may morph into time 
dilation.  
Because of the risk of nausea and vomiting, please refrain from eating and 
drinking for at least the 6 hours preceding the session. On the day of treatment, 
if you eat prior to the 6-hour fasting period, eat lightly. Hydrate well prior to the 
6-hour fasting period.
If you are unduly nauseated, you may be offered an anti-nausea medication—
odansetron—either orally or by injection.
Ketamine generally causes a significant increase in blood pressure but ususally 
not pulse rate. If blood pressure monitoring reveals that your blood pressure is too 
high, you may be offered clonidine to remedy this.
Agitation may occur during the course of a ketamine session. If your agitation 
is severe, you may be offered lorazepam orally or by injection to help you relax.
The administration of ketamine may also cause the following adverse reactions: 
tachycardia (elevation of pulse), diplopia (double vision), nystagmus (rapid eye movements), 
elevation of intraocular pressure (feeling of pressure in the eyes), and anorexia (loss of 
appetite). The above reactions occurred after rapid intravenous administration of ketamine or 
intramuscular administration of high doses of ketamine (in a range of greater than 5 mg/kg 
used for a surgical anesthesia. The dose to be used in this sub-anesthetic ketamine therapy is 
much lower (2 mg/kg or less).
Driving an automobile or engaging in hazardous activities should not be undertaken 
for 6 hours after treatment with ketamine and definitively until all effects have stopped if for 
any reason they continue longer.
In terms of psychological risk, ketamine has been shown to worsen certain psychotic 
symptoms in people who suffer from Schizophrenia or other serious Mental Disorders. It may 
also worsen underlying psychological problems in people with severe Personality Disorders. If 
you have been or are presently diagnosed with similar severe Mental Disorders, you may not 
be a candidate for KAP.
During the experience itself, some people have reported frightening, unusual experiences. 
These frightening experiences, however, may be of paramount value to your transition to recovery 
from the suffering that brought you to your KAP work. You will receive psyhotherapeutic help 
and ongoing guidance from your therapist.
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Potential for Ketamine Abuse and Physical Dependence
Ketamine belongs to the same group of chemicals as Phencyclidine (Sernyl, PCP, “Angel dust”). This group of chemical compounds is known chemically as Arylcyclohexylamines 
and is classified as Hallucinogens (“Psychedelics”). Ketamine is a controlled substance and is 
subject to Schedule III rules under the Controlled Substance Act of 1970. Medical evidence 
regarding the issue of drug abuse and dependence suggests that ketamine’s abuse potential is 
equivalent to that of phencyclidine and other hallucinogenic substances. 
Phencyclidine and other hallucinogenic compounds do not meet criteria for chemical 
dependence, since they do not cause tolerance and withdrawal symptoms. However, “cravings” 
have been reported by individuals with a history of heavy use of “psychedelic” drugs. In 
addition, ketamine can have effects on mood (feelings), cognition (thinking), and perception 
(imagery) that may make some people want to use it repeatedly. Therefore, ketamine should 
never be used except under the direct supervision of a licensed physician.
Alternative Procedures and Possibilities
No other procedure is available in medicine that produces ketamine’s effects. Major Depression (MDD) and Bipolar Disorders are usually treated with anti-depressant 
medications, tranquilizers, mood stabilizers, and psychotherapy. Electroconvulsive therapy 
(ECT), and the recently introduced Transcranial Magnetic Stimulation (TMS), are also in use 
for treatment-resistant-depression. Ketamine has also been used in the treatment of addictions 
and alcoholism as part of comprehensive and usually residential treatment programs, primarily 
abroad.
Confidentiality
Your privacy and all therapy records will be kept confidential. They will be maintained with the same precautions as ordinary medical records. To allow others access to your records, 
you will have to provide a signed release form. The results of this ketamine therapy may be 
published in clinical literature. Published reports will not include your name or any other 
information that would identify you.
Voluntary Nature of Participation
Please be aware that the Food and Drug Administration (FDA) has not yet established the appropriateness of Ketamine Assisted Psychotherapy, and its use is considered off-label, the 
only official “indication” for use of ketamine being anesthesia. Your awareness of this situation 
is key to understanding any liability associated with your use of ketamine. Your informed 
consent indicates you are aware of this situation. 
Ketamine is a new psychiatric treatment—the primary studies have been with depression, 
bipolar disorders, and alcoholism. It is not yet a mainstream treatment, though there are now 
many studies that demonstrate that it may be an effective treatment. That effect generally 
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occurs with more than one treatment and is most robust when part of an overall treatment 
program. It may not permanently relieve depression. If your depressive symptoms respond 
to Ketamine Assisted Psychotherapy, you may still elect to be treated with medications and 
ongoing psychotherapy to try to reduce the possibility of relapse. Over time, you may also need 
additional ketamine treatments or other therapies to maintain your remission.  
Your decision to undertake Ketamine  Assisted Psychotherapy is completely voluntary. 
Before you make your decision about participating in KAP, you may ask and will be encouraged 
to ask any questions you may have about the process. 
Withdrawal From KAP is Always Your Right!!!
Even after agreeing to undertake Ketamine Assisted Psychotherapy, you may decide to withdraw from treatment at any time. 
REMEMBER:
You are to have no food or drink 6 hours prior to the Ketamine session.
You will need to have someone drive you home from the sessions, and you must 
not engage in any driving or hazardous activity for at least 6 hours or more—
depending on the continued presence of effects after the session has concluded. 
Informed Consent 
By signing this form I agree that:
1. I have fully read this informed consent form describing Ketamine Assisted Psychotherapy.
2. I have had the opportunity to raise questions and have received satisfactory answers.
3. I fully understand that the ketamine session(s) can result in a profound change in mental 
state and may result in unusual psychological and physiological effects.
4.  I understand that I am to have no food or drink for 6 hours prior to my Ketamine 
session.
5.  I understand that I need to make arrangements to have someone drive me home from 
the Ketamine sessions.
6.  I agree that I will not engage in any driving or hazardous activity for at least 6 hours or 
longer after my session has concluded, and that I will not engage in any such activities 
until the effects of the Ketamine-induced state are no longer present.
7. I give my consent to the use of lorazepam if deemed necessary for agitation, to odansetron 
for nausea, and for clonidine for high blood pressure.
5.  I have been given a signed copy of this informed consent form, which is mine to keep.
6. I understand the risks and benefits, and I freely give my consent to participate in KAP 
as outlined in this form, and under the conditions indicated in it.
7. I understand that I may withdraw from KAP at any time, up until the actual injection 
has been given.
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Signature
Date
Printed Name
Physician / Therapist Statement
I have carefully explained the nature of Ketamine Assisted Psychotherapy to 
                                                  . I hereby certify that to the best of my knowledge, the 
individual signing this consent form understands the nature, conditions, risks and potential 
benefits involved in participating in KAP.
A medical problem or language or educational barrier has not precluded a clear understanding 
of the subject’s involvement in KAP.
Signature of Physician / Therapist
Date 
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